ISDA: 6W50

6W50 image

Deposition Date 2020-03-12

Release Date 2020-06-10

Last Version Date 2024-10-23

Entry Detail

PDB ID:

6W50

Keywords:

HYDROLASE/HYDROLASE INHIBITOR

Title:

FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((10R,14S)- 14-(4-(3-CHLORO-2,6-DIFLUOROPHENYL)-6-OXO-3,6-DIHYDRO- 1(2H)-PYRIDINYL)-10-METHYL-9-OXO-8,16- DIAZATRICYCLO[13.3.1.0~2,7~]NONADECA-1(19),2,4,6,15,17- HEXAEN-5-YL)CARBAMATE

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli BL21(DE3)

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.95 Å

R-Value Free:

0.17

R-Value Work:

0.15

R-Value Observed:

0.15

Space Group:

P 32 2 1

6W50 validation report

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Coagulation factor XI
Gene (Uniprot):F11
Chain IDs:A
Chain Length:244
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P03951 Pfam ID:PF00089 EC:3.4.21.27

Ligand Molecules

EDO

SO4

SWP

Primary Citation

Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species.

Yang, W, Wang, Y, Lai, A, Clark, C.G, Corte, J.R, Fang, T, Gilligan, P.J, Jeon, Y, Pabbisetty, K.B, Rampulla, R.A, Mathur, A, Kaspady, M, Neithnadka, P.R, Arumugam, A, Raju, S, Rossi, K.A, Myers Jr, J.E, Sheriff, S, Lou, Z, Zheng, J.J, Chacko, S.A, Bozarth, J.M, Wu, Y, Crain, E.J, Wong, P.C, Seiffert, D.A, Luettgen, J.M, Lam, P.Y.S, Wexler, R.R, Ewing, W.R, Quan, M.L, Wong, P.C, Wang, C, Woerner, F, Smallheer, J.M, Barbera, F.A, Bozarth, J.M, Brown, R.L, Harpel, M.R, Luettgen, J.M, Morin, P.E, Peterson, T, Ramamurthy, V, Rendina, A.R, Rossi, K.A, Watson, C.A, Wei, A, Zhang, G, Seiffert, D, Wexler, R.R, Quan, M.L, Wong, P.C, Wang, C, Woerner, F, Smallheer, J.M, Barbera, F.A, Bozarth, J.M, Brown, R.L, Harpel, M.R, Luettgen, J.M, Morin, P.E, Peterson, T, Ramamurthy, V, Rendina, A.R, Rossi, K.A, Watson, C.A, Wei, A, Zhang, G, Seiffert, D, Wexler, R.R, Hangeland, J.J, Friends, T.J, Rossi, K.A, Smallheer, J.M, Wang, C, Sun, Z, Corte, J.R, Fang, T, Wong, P.C, Rendina, A.R, Barbera, F.A, Bozarth, J.M, Luettgen, J.M, Watson, C.A, Zhang, G, Wei, A, Ramamurthy, V, Morin, P.E, Bisacchi, G.S, Subramaniam, S, Arunachalam, P, Mathur, A, Seiffert, D.A, Wexler, R.R, Quan, M.L, Corte, J.R, Fang, T, Hangeland, J.J, Friends, T.J, Rendina, A.R, Luettgen, J.M, Bozarth, J.M, Barbera, F.A, Rossi, K.A, Wei, A, Ramamurthy, V, Morin, P.E, Seiffert, D.A, Wexler, R.R, Quan, M.L, Pinto, D.J, Smallheer, J.M, Corte, J.R, Austin, E.J, Wang, C, Fang, T, Smith II, L.M, Rossi, K.A, Rendina, A.R, Bozarth, J.M, Zhang, G, Wei, A, Ramamurthy, V, Sheriff, S, Myers Jr, J.E, Morin, P.E, Luettgen, J.M, Seiffert, D.A, Quan, M.L, Wexler, R.R, Hu, Z, Wong, P.C, Gilligan, P.J, Han, W, Pabbisetty, K.B, Bozarth, J.M, Crain, E.J, Harper, T, Luettgen, J.M, Myers Jr, J.E, Ramamurthy, V, Rossi, K.A, Sheriff, S, Watson, C.A, Wei, A, Zheng, J.J, Seiffert, D.A, Wexler, R.R, Quan, M.L, Smith II, L.M, Orwat, M.J, Hu, Z, Han, W, Wang, C, Rossi, K.A, Gilligan, P.J, Pabbisetty, K.B, Osuna, H, Corte, J.R, Rendina, A.R, Luettgen, J.M, Wong, P.C, Narayanan, R, Harper, T.W, Bozarth, J.M, Crain, E.J, Wei, A, Ramamurthy, V, Morin, P.E, Xin, B, Zheng, J, Seiffert, D.A, Quan, M.L, Lam, P.Y.S, Wexler, R.R, Pinto, D.J.P, Corte, J.R, Fang, T, Pinto, D.J, Orwat, M.J, Rendina, A.R, Luettgen, J.M, Rossi, K.A, Wei, A, Ramamurthy, V, Myers Jr, J.E, Sheriff, S, Narayanan, R, Harper, T.W, Zheng, J.J, Li, Y.X, Seiffert, D.A, Wexler, R.R, Quan, M.L, Corte, J.R, Fang, T, Osuna, H, Pinto, D.J, Rossi, K.A, Myers Jr, J.E, Sheriff, S, Lou, Z, Zheng, J.J, Harper, T.W, Bozarth, J.M, Wu, Y, Luettgen, J.M, Seiffert, D.A, Decicco, C.P, Wexler, R.R, Quan, M.L, Corte, J.R, Yang, W, Fang, T, Wang, Y, Osuna, H, Lai, A, Ewing, W.R, Rossi, K.A, Myers Jr, J.E, Sheriff, S, Lou, Z, Zheng, J.J, Harper, T.W, Bozarth, J.M, Wu, Y, Luettgen, J.M, Seiffert, D.A, Quan, M.L, Wexler, R.R, Lam, P.Y.S, Wang, C, Corte, J.R, Rossi, K.A, Bozarth, J.M, Wu, Y, Sheriff, S, Myers Jr, J.E, Luettgen, J.M, Seiffert, D.A, Wexler, R.R, Quan, M.L, Pinto, D.J.P, Orwat, M.J, Smith II, L.M, Quan, M.L, Lam, P.Y.S, Rossi, K.A, Apedo, A, Bozarth, J.M, Wu, Y, Zheng, J.J, Xin, B, Toussaint, N, Stetsko, P, Gudmundsson, O, Maxwell, B, Crain, E.J, Wong, P.C, Lou, Z, Harper, T.W, Chacko, S.A, Myers Jr, J.E, Sheriff, S, Zhang, H, Hou, X, Mathur, A, Seiffert, D.A, Wexler, R.R, Luettgen, J.M, Ewing, W.R, Clark, C.G, Rossi, K.A, Corte, J.R, Fang, T, Smallheer, J.M, De Lucca, I, Nirschl, D.S, Orwat, M.J, Pinto, D.J.P, Hu, Z, Wang, Y, Yang, W, Jeon, Y, Ewing, W.R, Myers Jr, J.E, Sheriff, S, Lou, Z, Bozarth, J.M, Wu, Y, Rendina, A, Harper, T, Zheng, J, Xin, B, Xiang, Q, Leuttgen, J.M, Seiffert, D.A, Wexler, R.R, Lam, P.Y.S, Corte, J.R, Pinto, D.J.P, Fang, T, Osuna, H, Yang, W, Wang, Y, Lai, A, Clark, C.G, Sun, J.-H, Rampulla, R, Mathur, A, Kaspady, M, Neithnadka, P.R, Li, Y.-X.C, Rossi, K.A, Myers Jr, J.E, Sheriff, S, Lou, Z, Harper, T.W, Huang, C, Zheng, J.J, Bozarth, J.M, Wu, Y, Wong, P.C, Crain, E.J, Seiffert, D.A, Luettgen, J.M, Lam, P.Y.S, Wexler, R.R, Ewing, W.R, Fang, T, Corte, J.R, Gilligan, P.J, Jeon, Y, Osuna, H, Rossi, K.A, Myers Jr, J.E, Sheriff, S, Lou, Z, Zheng, J.J, Harper, T.W, Bozarth, J.M, Wu, Y, Luettgen, J.M, Seiffert, D.A, Wexler, R.R, Lam, P.Y.S.Show

J.Med.Chem. 63 7226 7242 (2020)

PMID: 32456431 DOI: 10.1021/acs.jmedchem.0c00464

Abstact

Oral factor XIa (FXIa) inhibitors may provide a promising new antithrombotic therapy with an improved benefit to bleeding risk profile over existing antithrombotic agents. Herein, we report application of a previously disclosed cyclic carbamate P1 linker which provided improved oral bioavailability in the imidazole-based 13-membered macrocycle to the 12-membered macrocycle. This resulted in identification of compound 4 with desired FXIa inhibitory potency and good oral bioavailability but high in vivo clearance. Further structure-activity relationship (SAR) studies of heterocyclic core modifications to replace the imidazole core as well as various linkers to the P1 group led to the discovery of compound 6f, a potent FXIa inhibitor with selectivity against most of the relevant serine proteases. Compound 6f also demonstrated excellent pharmacokinetics (PK) profile (high oral bioavailability and low clearance) in multiple preclinical species. Compound 6f achieved robust antithrombotic efficacy in a rabbit efficacy model at doses which preserved hemostasis.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

6W50